

---

**Product Name: PBFE Rabbit Polyclonal Antibody****Catalog #: APRab15804**

For research use only.

**Summary**

<b>Description</b>	Rabbit polyclonal Antibody
<b>Host</b>	Rabbit
<b>Application</b>	WB,IHC,ICC/IF,ELISA
<b>Reactivity</b>	Human,Rat
<b>Conjugation</b>	Unconjugated
<b>Modification</b>	Unmodified
<b>Isotype</b>	IgG
<b>Clonality</b>	Polyclonal
<b>Form</b>	Liquid
<b>Concentration</b>	1mg/ml
<b>Storage</b>	Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.
<b>Shipping</b>	Ice bags
<b>Buffer</b>	Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type preservative N.
<b>Purification</b>	Affinity purification

**Application**

<b>Dilution Ratio</b>	WB 1:500-1:2000,IHC 1:100-1:300,ICC/IF 1:50-1:200,ELISA 1:5000-1:20000
<b>Molecular Weight</b>	80kDa

**Antigen Information**

<b>Gene Name</b>	EHHADH
<b>Alternative Names</b>	EHHADH; ECHD; Peroxisomal bifunctional enzyme; PBE; PBFE
<b>Gene ID</b>	1962.0
<b>SwissProt ID</b>	Q08426
<b>Immunogen</b>	The antiserum was produced against synthesized peptide derived from human EHHADH. AA range:476-525

**Background**


catalytic activity:(3S)-3-hydroxyacyl-CoA = trans-2(or 3)-enoyl-CoA + H(2)O.,catalytic activity:(3Z)-dodec-3-enoyl-CoA = (2E)-

dodec-2-enoyl-CoA.,catalytic activity:(S)-3-hydroxyacyl-CoA + NAD(+) = 3-oxoacyl-CoA + NADH.,disease:Absent in patients suffering with peroxisomal disorders such as Zellweger syndrome, neonatal adrenoleukodystrophy and infantile Refsum disease.,pathway:Lipid metabolism; fatty acid beta-oxidation.,similarity:In the C-terminal section; belongs to the 3-hydroxyacyl-CoA dehydrogenase family.,similarity:In the N-terminal section; belongs to the enoyl-CoA hydratase/isomerase family.,subunit:Monomer.,tissue specificity:Liver and kidney. Lower amounts seen in the brain.,catalytic activity:(3S)-3-hydroxyacyl-CoA = trans-2(or 3)-enoyl-CoA + H(2)O.,catalytic activity:(3Z)-dodec-3-enoyl-CoA = (2E)-dodec-2-enoyl-CoA.,catalytic activity:(S)-3-hydroxyacyl-CoA + NAD(+) = 3-oxoacyl-CoA + NADH.,disease:Absent in patients suffering with peroxisomal disorders such as Zellweger syndrome, neonatal adrenoleukodystrophy and infantile Refsum disease.,pathway:Lipid metabolism; fatty acid beta-oxidation.,similarity:In the C-terminal section; belongs to the 3-hydroxyacyl-CoA dehydrogenase family.,similarity:In the N-terminal section; belongs to the enoyl-CoA hydratase/isomerase family.,subunit:Monomer.,tissue specificity:Liver and kidney. Lower amounts seen in the brain.,


## Research Area

Fatty acid metabolism;Valine; leucine and isoleucine degradation;Lysine degradation;Tryptophan metabolism;beta-Alanine metabolism;Propanoate metabolism;Butanoate metabolism;Limonene and pinene degradation;PPAR;


## Image Data




Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using EHHADH Antibody. The picture on the right is blocked with the synthesized peptide.




Western blot analysis of lysates from A549 cells, using EHHADH Antibody. The lane on the right is blocked with the synthesized peptide.



Western blot analysis of the lysates from HepG2 cells using EHHADH antibody.



Western Blot analysis of various cells using PBFE Polyclonal Antibody



Western Blot analysis of A549 cells using PBFE Polyclonal Antibody